Share

    


Home / Search Results

Search Results

You searched for:

In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland; Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina; and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt …
As CAR T-cell therapies provide new treatment options for patients with certain hematologic malignancies, it is important that more cancer centers and programs deliver them.
ACCC in partnership with HealthTree Foundation for Acute Myeloid Leukemia, has launched an education program to explore the current barriers in care coordination and therapy options for patients with AML who are not eligible for transplant.
ACCC set out to identify and understand specific regional challenges to appropriate and equitable care for patients with chronic lymphocytic leukemia, the most common form of leukemia in adults.
ACCCBuzz spoke with Dr. Gabriela Hobbs, MD, at Massachusetts General Hospital Cancer Center to learn how to best manage patients' care for those with myelofibrosis.
Allen Beck and Rivka Beck were newly weds when Allen was diagnosed with myelodysplastic syndrome. A month before he was scheduled to complete a bone marrow transplant, he lost the insurance coverage provided by his university. Angie Santiago, CRCS, the manager of Oncology Financial Advocacy at Sidney Kimmel Cancer Center at the Thomas Jefferson University Health System in Philadelphia, Pa, made sure …
March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.
The purpose of this study was to assess patient, disease, and medication-related factors that affect the rate of unplanned readmissions before next chemotherapy cycle or within 30 days since last chemotherapy admission in patients with hematologic malignancies.